{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:48:38Z","timestamp":1790304518874,"version":"4.1.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ministry of Science, Sports and Culture, Japan","award":["21H02675"],"award-info":[{"award-number":["21H02675"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mutations in the <jats:italic>KRAS<\/jats:italic> gene and overexpression of protein products of the <jats:italic>MYC<\/jats:italic> and <jats:italic>ARF6<\/jats:italic> genes occur frequently in cancer. Here, the inseparable relationships and cooperation of the protein products of these three genes in cancer malignancy and immune evasion are discussed. mRNAs encoded by these genes share the common feature of a G-quadruplex structure, which directs them to be robustly expressed when cellular energy production is increased. These three proteins are also functionally inseparable from each other, as follows.\u30001) KRAS induces <jats:italic>MYC<\/jats:italic> gene expression, and may also promote eIF4A-dependent <jats:italic>MYC<\/jats:italic> and <jats:italic>ARF6<\/jats:italic> mRNA translation, 2) MYC induces the expression of genes involved in mitochondrial biogenesis and oxidative phosphorylation, and 3) ARF6 protects mitochondria from oxidative injury. ARF6 may moreover promote cancer invasion and metastasis, and also acidosis and immune checkpoint. Therefore, the inseparable relationships and cooperation of KRAS, MYC, and ARF6 appear to result in the activation of mitochondria and the driving of ARF6-based malignancy and immune evasion. Such adverse associations are frequent in pancreatic cancer, and appear to be further enhanced by <jats:italic>TP53<\/jats:italic> mutations.<\/jats:p>","DOI":"10.1186\/s12964-023-01130-3","type":"journal-article","created":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T10:02:19Z","timestamp":1683540139000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["KRAS, MYC, and ARF6: inseparable relationships cooperatively promote cancer malignancy and immune evasion"],"prefix":"10.1186","volume":"21","author":[{"given":"Hisataka","family":"Sabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,8]]},"reference":[{"key":"1130_CR1","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-11-2612","volume":"72","author":"IA Prior","year":"2012","unstructured":"Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res. 2012;72:2457\u201367.","journal-title":"Cancer Res"},{"key":"1130_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41392-018-0008-7","volume":"3","author":"H Chen","year":"2018","unstructured":"Chen H, Liu H, Qing G. Targeting oncogenic Myc as a strategy for cancer treatment. Signal Transduct Target Ther. 2018;3:5.","journal-title":"Signal Transduct Target Ther"},{"key":"1130_CR3","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1093\/jb\/mvg181","volume":"134","author":"H Sabe","year":"2003","unstructured":"Sabe H. Requirement for Arf6 in cell adhesion, migration, and cancer cell invasion. J Biochem. 2003;134:485\u20139.","journal-title":"J Biochem"},{"key":"1130_CR4","doi-asserted-by":"publisher","first-page":"a001008","DOI":"10.1101\/cshperspect.a001008","volume":"2","author":"M Olivier","year":"2010","unstructured":"Olivier M, Hollstaein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010;2:a001008.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"1130_CR5","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ccell.2017.07.007","volume":"32","author":"BJ Raphael","year":"2017","unstructured":"Raphael BJ, et al. Integrated cenomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell. 2017;32:185\u2013203.","journal-title":"Cancer Cell"},{"key":"1130_CR6","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/gcc.10122","volume":"35","author":"EH Mahlamaki","year":"2002","unstructured":"Mahlamaki EH, et al. Frequent amplification of 8q24, 11q, 17q, and 20q-specific genes in pancreatic cancer. Genes Chrom Cancer. 2002;35:353\u20138.","journal-title":"Genes Chrom Cancer"},{"key":"1130_CR7","doi-asserted-by":"publisher","first-page":"17450","DOI":"10.1073\/pnas.1901765116","volume":"116","author":"H Hashimoto","year":"2019","unstructured":"Hashimoto H, et al. ARF6 and AMAP1 are major targets of\u00a0KRAS\u00a0and\u00a0TP53 mutations to promote invasion, PD-L1 dynamics, and immune evasion of pancreatic cancer. Proc Natl Acad Sci USA. 2019;116:17450\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1130_CR8","doi-asserted-by":"publisher","first-page":"16425","DOI":"10.1038\/s41598-020-73525-y","volume":"10","author":"A Bengtsson","year":"2020","unstructured":"Bengtsson A, Andersson R, Ansari D. The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data. Sci Rep. 2020;10:16425.","journal-title":"Sci Rep"},{"key":"1130_CR9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/nature13485","volume":"513","author":"AL Wolfe","year":"2014","unstructured":"Wolfe AL, et al. RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer. Nature. 2014;513:65\u201370.","journal-title":"Nature"},{"key":"1130_CR10","doi-asserted-by":"publisher","first-page":"6647","DOI":"10.1073\/pnas.0401753101","volume":"101","author":"S Hashimoto","year":"2004","unstructured":"Hashimoto S, et al. Requirement for Arf6 in breast cancer invasive activities. Proc Natl Acad Sci USA. 2004;101:6647\u201352.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1130_CR11","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1158\/0008-5472.CAN-03-0846","volume":"64","author":"F Schwartzenberg-Bar-Yoseph","year":"2004","unstructured":"Schwartzenberg-Bar-Yoseph F, Armoni M, Karnieli E. The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res. 2004;64:2627\u201333.","journal-title":"Cancer Res"},{"key":"1130_CR12","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/sj.onc.1201520","volume":"16","author":"E Kerkhoff","year":"1998","unstructured":"Kerkhoff E, et al. Regulation of c-myc expression by Ras\/Raf signalling. Oncogene. 1998;16:211\u20136.","journal-title":"Oncogene"},{"key":"1130_CR13","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12964-021-00733-y","volume":"18","author":"A Hashimoto","year":"2021","unstructured":"Hashimoto A, et al. Inhibition of mutant KRAS-driven overexpression of ARF6 and MYC by an eIF4A inhibitor drug improves the effects of anti-PD-1 immunotherapy for pancreatic cancer. Cell Comm Signal. 2021;18:54.","journal-title":"Cell Comm Signal"},{"key":"1130_CR14","unstructured":"https:\/\/cancer.sanger.ac.uk\/cosmic"},{"key":"1130_CR15","doi-asserted-by":"publisher","first-page":"3722","DOI":"10.1038\/s41467-019-11530-0","volume":"10","author":"IG Serebriiski","year":"2019","unstructured":"Serebriiski IG, et al. Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients. Nat Commun. 2019;10:3722.","journal-title":"Nat Commun"},{"key":"1130_CR16","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.cub.2012.11.031","volume":"23","author":"B Lampson","year":"2013","unstructured":"Lampson B, et al. Rare codons regulate KRas oncogenesis. Curr Biol. 2013;23:70\u20135.","journal-title":"Curr Biol"},{"key":"1130_CR17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0959-437X(98)80061-0","volume":"8","author":"J Downward","year":"1998","unstructured":"Downward J. Ras signalling and apoptosis. Curr Opin Genet Dev. 1998;8:49\u201354.","journal-title":"Curr Opin Genet Dev"},{"key":"1130_CR18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/nrm3255","volume":"13","author":"IM Ahearn","year":"2011","unstructured":"Ahearn IM, Haigis K, Bar-Sagi D, Phillips MR. Regulating the regulator: post-translational modification of RAS. Nat Rev Mol Cell Biol. 2011;13:39.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1130_CR19","doi-asserted-by":"publisher","first-page":"a031484","DOI":"10.1101\/cshperspect.a031484","volume":"8","author":"IM Ahearn","year":"2018","unstructured":"Ahearn IM, Zhou M, Phillips MR. Posttranslational modifications of RAS proteins. Cold Spring Harb Perspect Med. 2018;8:a031484.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"1130_CR20","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.sbi.2021.06.015","volume":"71","author":"SL Campbell","year":"2021","unstructured":"Campbell SL, Phillips MR. Post-translational modification of RAS proteins. Curr Opin Struct Biol. 2021;71:180.","journal-title":"Curr Opin Struct Biol"},{"key":"1130_CR21","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1158\/2159-8290.CD-12-0231","volume":"3","author":"A Young","year":"2013","unstructured":"Young A, Lou D, McCormick F. Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling. Cancer Discov. 2013;3:112\u201323.","journal-title":"Cancer Discov"},{"key":"1130_CR22","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1096\/fj.04-2273com","volume":"18","author":"Y Li","year":"2004","unstructured":"Li Y, et al. Functional genomic analysis of the ADP-ribosylation factor family of GTPases: phylogeny among diverse eukaryotes and function in C. elegans. Faseb J. 2004;18:1834\u201350.","journal-title":"Faseb J"},{"key":"1130_CR23","doi-asserted-by":"publisher","first-page":"evab157","DOI":"10.1093\/gbe\/evab157","volume":"13","author":"R Vargova","year":"2021","unstructured":"Vargova R, et al. A Eukaryote-wide perspective on the diversity and evolution of the ARF GTPase protein family. Genome Biol Evol. 2021;13:evab157.","journal-title":"Genome Biol Evol"},{"key":"1130_CR24","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nrm1910","volume":"7","author":"CP D'Souza-Schorey","year":"2006","unstructured":"D\u2019Souza-Schorey CP. ARF proteins: roles in membrane traffic and beyond. Nat Rev Mol Cell Biol. 2006;7:347\u201358.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1130_CR25","doi-asserted-by":"publisher","first-page":"41573","DOI":"10.1074\/jbc.R300026200","volume":"278","author":"JG Donaldson","year":"2003","unstructured":"Donaldson JG. Multiple roles for Arf6: sorting, structuring, and signaling at the plasma membrane. J Biol Chem. 2003;278:41573\u20136.","journal-title":"J Biol Chem"},{"key":"1130_CR26","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1093\/jb\/mvg181","volume":"134","author":"H Sabe","year":"2003","unstructured":"Sabe H. Requirement for Arf6 in cell adhesion, migration, and cancer cell Invasion. J Biochem. 2003;134:485\u20139.","journal-title":"J Biochem"},{"key":"1130_CR27","doi-asserted-by":"publisher","first-page":"6647","DOI":"10.1073\/pnas.0401753101","volume":"101","author":"S Hashimoto","year":"2004","unstructured":"Hashimoto S, et al. Requirement for Arf6 in breast cancer invasive activities. Proc Natl Acad Sci USA. 2004;101:6647\u201352.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1130_CR28","doi-asserted-by":"publisher","first-page":"e25301","DOI":"10.1371\/journal.pone.0025301","volume":"6","author":"T Menju","year":"2011","unstructured":"Menju T, et al. Engagement of overexpressed Her2 with GEP100 induces autonomous invasive activities and provides a biomarker for metastases of lung adenocarcinoma. PLoS ONE. 2011;6:e25301.","journal-title":"PLoS ONE"},{"key":"1130_CR29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1478-811X-12-17","volume":"12","author":"H Sato","year":"2014","unstructured":"Sato H, et al. High level expression of AMAP1 protein correlates with poor prognosis and survival after surgery of head and neck squamous cell carcinoma patients. Cell Comm Signal. 2014;12:17.","journal-title":"Cell Comm Signal"},{"key":"1130_CR30","doi-asserted-by":"publisher","first-page":"10656","DOI":"10.1038\/ncomms10656","volume":"7","author":"S Hashimoto","year":"2016","unstructured":"Hashimoto S, et al. Lysophosphatidic acid activates Arf6 to promote the mesenchymal malignancy of renal cancer. Nat Commun. 2016;7:10656.","journal-title":"Nat Commun"},{"key":"1130_CR31","unstructured":"https:\/\/www.proteinatlas.org\/ENSG00000165527-ARF6\/pathology"},{"key":"1130_CR32","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/sj.emboj.7600588","volume":"24","author":"Y Onodera","year":"2005","unstructured":"Onodera Y, et al. Expression of AMAP1, an ArfGAP, provides novel targets to inhibit breast cancer invasive activities. EMBO J. 2005;24:963\u201373.","journal-title":"EMBO J"},{"key":"1130_CR33","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1083\/jcb.201201065","volume":"197","author":"Y Onodera","year":"2012","unstructured":"Onodera Y, et al. Rab5c promotes AMAP1-PRKD2 complex formation to enhance \u03b21 integrin recycling in EGF-induced cancer invasion. J Cell Biol. 2012;197:983\u201396.","journal-title":"J Cell Biol"},{"key":"1130_CR34","doi-asserted-by":"publisher","first-page":"e259","DOI":"10.1038\/oncsis.2016.60","volume":"5","author":"A Hashimoto","year":"2016","unstructured":"Hashimoto A, et al. ZEB1 induces EPB41L5 in the cancer mesenchymal program that drives ARF6-based invasion, metastasis, and drug resistance. Oncogenesis. 2016;5:e259.","journal-title":"Oncogenesis"},{"key":"1130_CR35","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1083\/jcb.200712086","volume":"182","author":"M Hirano","year":"2008","unstructured":"Hirano M, et al. EPB41L5 functions to post-transcriptionally regulate cadherin and integrin during epithelial-mesenchymal transition. J Cell Biol. 2008;182:1217\u201330.","journal-title":"J Cell Biol"},{"key":"1130_CR36","doi-asserted-by":"publisher","first-page":"4741","DOI":"10.1038\/onc.2010.215","volume":"29","author":"A Singh","year":"2010","unstructured":"Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evel in the war on cancer. Oncogene. 2010;29:4741.","journal-title":"Oncogene"},{"key":"1130_CR37","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/1878-0261.12093","volume":"11","author":"S Terry","year":"2017","unstructured":"Terry S, et al. New insights into the role of EMT in tumor immune escape. Mol Oncol. 2017;11:824.","journal-title":"Mol Oncol"},{"key":"1130_CR38","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1007\/s00204-021-03063-7","volume":"95","author":"RJ De Las","year":"2021","unstructured":"De Las RJ, et al. Cancer drug resistance induced by EMT: novel therapeutic strategies. Arch Toxicol. 2021;95:2279.","journal-title":"Arch Toxicol"},{"key":"1130_CR39","doi-asserted-by":"publisher","first-page":"e108647","DOI":"10.15252\/embj.2021108647","volume":"40","author":"S Brabletz","year":"2021","unstructured":"Brabletz S, Schuhwerk H, Brabletz T, Stemmler MP. Dynamic EMT: a multi-tool for tumor progression. EMBO J. 2021;40:e108647.","journal-title":"EMBO J"},{"key":"1130_CR40","doi-asserted-by":"publisher","first-page":"101258","DOI":"10.1016\/j.tranon.2021.101258","volume":"15","author":"M Horikawa","year":"2022","unstructured":"Horikawa M, et al. Dual roles of AMAP1 in the transcriptional regulation and intracellular trafficking of carbonic anhydrase IX. Transl Oncol. 2022;15:101258.","journal-title":"Transl Oncol"},{"key":"1130_CR41","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1038\/s41467-018-05087-7","volume":"9","author":"Y Onodera","year":"2018","unstructured":"Onodera Y, et al. Arf6-driven cell invasion is intrinsically linked to TRAK1-mediated mitochondrial anterograde trafficking to avoid oxidative catastrophe. Nat Commun. 2018;9:2682.","journal-title":"Nat Commun"},{"key":"1130_CR42","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/ncb1672","volume":"10","author":"M Morishige","year":"2008","unstructured":"Morishige M, et al. GEP100 links epidermal growth factor receptor signaling to Arf6 activation to induce breast cancer invasion. Nat Cell Biol. 2008;10:85\u201392.","journal-title":"Nat Cell Biol"},{"key":"1130_CR43","doi-asserted-by":"publisher","first-page":"7038","DOI":"10.1128\/MCB.18.12.7038","volume":"18","author":"MT Brown","year":"1998","unstructured":"Brown MT, et al. ASAP1, a phospholipid-dependent Arf GTPase-activating protein that associates with and is phosphorylated by Src. Mol Cell Biol. 1998;18:7038\u201351.","journal-title":"Mol Cell Biol"},{"key":"1130_CR44","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.ceb.2006.08.002","volume":"18","author":"H Sabe","year":"2006","unstructured":"Sabe H, et al. ArfGAP family proteins in cell adhesion, migration and tumor invasion. Curr Opin Cell Biol. 2006;18:558\u201364.","journal-title":"Curr Opin Cell Biol"},{"key":"1130_CR45","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.cell.2010.03.051","volume":"141","author":"SA Ismail","year":"2010","unstructured":"Ismail SA, et al. The structure of an Arf-ArfGAP complex reveals a Ca2+ regulatory mechanism. Cell. 2010;141:812\u201321.","journal-title":"Cell"},{"key":"1130_CR46","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1083\/jcb.201510002","volume":"213","author":"A Hashimoto","year":"2016","unstructured":"Hashimoto A, et al. P53- and mevalonate pathway-driven malignancies require Arf6 for metastasis and drug resistance. J Cell Biol. 2016;213:81\u201395.","journal-title":"J Cell Biol"},{"key":"1130_CR47","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.cell.2011.12.017","volume":"148","author":"WA Freed-Pastor","year":"2012","unstructured":"Freed-Pastor WA, et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell. 2012;148:244\u201358.","journal-title":"Cell"},{"key":"1130_CR48","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.cell.2014.01.066","volume":"157","author":"S Weissmueller","year":"2014","unstructured":"Weissmueller S, et al. Mutant p53 drives pancreatic cancer metastasis through cell- autonomous PDGF receptor \u03b2 signaling. Cell. 2014;157:382\u201394.","journal-title":"Cell"},{"key":"1130_CR49","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12964-018-0302-6","volume":"16","author":"H Handa","year":"2018","unstructured":"Handa H, et al. Epithelial-specific histone modification of the miR-96\/182 locus targeting AMAP1 mRNA predisposes p53 to suppress cell invasion in epithelial cells. Cell Commun Signal. 2018;16:94.","journal-title":"Cell Commun Signal"},{"key":"1130_CR50","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/nrc3106","volume":"11","author":"Y Pylayeva-Gupta","year":"2011","unstructured":"Pylayeva-Gupta Y, Grabock E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 2011;11:761\u201374.","journal-title":"Nat Rev Cancer"},{"key":"1130_CR51","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/nrm3025","volume":"12","author":"R Zoncu","year":"2011","unstructured":"Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011;12:21\u201335.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1130_CR52","doi-asserted-by":"publisher","first-page":"R69","DOI":"10.1186\/gb-2003-4-10-r69","volume":"4","author":"KI Zeller","year":"2003","unstructured":"Zeller KI, et al. An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome Biol. 2003;4:R69.","journal-title":"Genome Biol"},{"key":"1130_CR53","doi-asserted-by":"publisher","first-page":"17834","DOI":"10.1073\/pnas.0604129103","volume":"103","author":"KI Zeller","year":"2006","unstructured":"Zeller KI, et al. Global mapping of c-Myc binding sites and target gene networks in human B cells. Proc Natl Acad Sci USA. 2006;103:17834\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1130_CR54","doi-asserted-by":"publisher","first-page":"6225","DOI":"10.1128\/MCB.25.14.6225-6234.2005","volume":"25","author":"F Li","year":"2005","unstructured":"Li F, et al. Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. Mol Cell Biol. 2005;25:6225\u201334.","journal-title":"Mol Cell Biol"},{"key":"1130_CR55","doi-asserted-by":"publisher","first-page":"e1798","DOI":"10.1371\/journal.pone.0001798","volume":"3","author":"J Kim","year":"2008","unstructured":"Kim J, Lee J, Iyer VR. Global identification of Myc target genes reveals its direct role in mitochondrial biogenesis and its E-Box usage in vivo. PLoS ONE. 2008;3:e1798.","journal-title":"PLoS ONE"},{"key":"1130_CR56","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1158\/1078-0432.CCR-14-2425","volume":"21","author":"AC Kimmelman","year":"2015","unstructured":"Kimmelman AC. Metabolic dependencies in RAS-driven cancers. Clin Cancer Res. 2015;21:1828\u201334.","journal-title":"Clin Cancer Res"},{"key":"1130_CR57","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1084\/jem.192.7.1001","volume":"192","author":"DB Zorov","year":"2000","unstructured":"Zorov DB, et al. Reactive oxygen species (ROS)-induced ROS release: a new phenomenon accompanying induction of the mitochondrial permeability transition in cardiac myocytes. J Exp Med. 2000;192:1001\u201314.","journal-title":"J Exp Med"},{"key":"1130_CR58","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.neuron.2012.11.027","volume":"77","author":"M van Spronsen","year":"2013","unstructured":"van Spronsen M, et al. TRAK\/Milton motor-adaptor proteins steer mitochondrial trafficking to axons and dendrites. Neuron. 2013;77:485\u2013502.","journal-title":"Neuron"},{"key":"1130_CR59","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.tcb.2014.05.002","volume":"24","author":"MM Fu","year":"2014","unstructured":"Fu MM, Holzbaur ELF. Integrated regulation of motor-driven organelle transport by scaffolding proteins. Trends Cell Biol. 2014;24:564\u201374.","journal-title":"Trends Cell Biol"},{"key":"1130_CR60","doi-asserted-by":"publisher","first-page":"102070","DOI":"10.1016\/j.ctrv.2020.102070","volume":"89","author":"D Uprety","year":"2020","unstructured":"Uprety D, Adjei AA. KRAS: from undruggable to a druggable cancer target. Cancer Treat Rev. 2020;89:102070.","journal-title":"Cancer Treat Rev"},{"key":"1130_CR61","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","volume":"6","author":"L Huang","year":"2021","unstructured":"Huang L, et al. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct Target Ther. 2021;6:386.","journal-title":"Signal Transduct Target Ther"},{"key":"1130_CR62","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.jacc.2013.04.088","volume":"62","author":"T Hasin","year":"2013","unstructured":"Hasin T, et al. Patients with heart failure have an increased risk of incident cancer. J Am Coll Cardiol. 2013;62:881\u20136.","journal-title":"J Am Coll Cardiol"},{"key":"1130_CR63","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/ejhf.472","volume":"18","author":"A Banke","year":"2016","unstructured":"Banke A, et al. Incidence of cancer in patients with chronic heart failure: a long-term follow- up study. Eur J Heart Fail. 2016;18:260\u20136.","journal-title":"Eur J Heart Fail"},{"key":"1130_CR64","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jacc.2016.04.053","volume":"68","author":"T Hasin","year":"2016","unstructured":"Hasin T, et al. Heart failure after myocardial infarction is associated with increased risk of cancer. J Am Coll Cardiol. 2016;68:265\u201371.","journal-title":"J Am Coll Cardiol"},{"key":"1130_CR65","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1038\/hr.2017.45","volume":"40","author":"M Sakamoto","year":"2017","unstructured":"Sakamoto M, et al. Does the pathophysiology of heart failure prime the incidence of cancer? Hypertens Res. 2017;40:831\u20136.","journal-title":"Hypertens Res"},{"key":"1130_CR66","doi-asserted-by":"publisher","first-page":"14709","DOI":"10.1038\/s41598-019-51298-3","volume":"9","author":"R Shirakawa","year":"2019","unstructured":"Shirakawa R, et al. Mitochondrial reactive oxygen species generation in blood cells is associated with disease severity and exercise intolerance in heart failure patients. Sci Rep. 2019;9:14709.","journal-title":"Sci Rep"},{"key":"1130_CR67","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1126\/science.1240527","volume":"342","author":"N Iida","year":"2013","unstructured":"Iida N, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science. 2013;342:969\u201370.","journal-title":"Science"},{"key":"1130_CR68","doi-asserted-by":"publisher","first-page":"1006322","DOI":"10.3389\/fonc.2022.1006322","volume":"12","author":"S Takada","year":"2022","unstructured":"Takada S, et al. Cross-disease communication between cancer and heart failure provides a rational approach to prevention and treatment of both diseases. Front Oncol. 2022;12:1006322.","journal-title":"Front Oncol"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-023-01130-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-023-01130-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-023-01130-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T16:33:53Z","timestamp":1684168433000},"score":1,"resource":{"primary":{"URL":"https:\/\/biosignaling.biomedcentral.com\/articles\/10.1186\/s12964-023-01130-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,8]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1130"],"URL":"https:\/\/doi.org\/10.1186\/s12964-023-01130-3","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,8]]},"assertion":[{"value":"4 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The author declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"106"}}